Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760498 | 0.84 | POLB (0.65) | HTTPOLBALDH1A1L3MBTL1LMNA | |
| SCHEMBL12479809 | 0.82 | HTT (0.55) | HTTPOLBALDH1A1L3MBTL1LMNA | |
| SCHEMBL6418088 | 0.82 | HTT (0.57) | HTTPOLBALDH1A1L3MBTL1LMNA | |
| SCHEMBL18354808 | 0.80 | NPC1 (0.56) | HTTPOLBALDH1A1LMNAMEN1 | |
| SCHEMBL16943099 | 0.79 | NPC1 (0.55) | HTTPOLBALDH1A1ATMLMNA | |
| SCHEMBL8657291 | 0.78 | HTT (0.57) | HTTPOLBALDH1A1L3MBTL1LMNA | |
| SCHEMBL1520529 | 0.76 | POLB (0.63) | HTTPOLBALDH1A1L3MBTL1LMNA | |
| SCHEMBL2066583 | 0.76 | NPC1 (0.59) | HTTPOLBALDH1A1LMNAKMT2A | |
| SCHEMBL16832768 | 0.75 | ALDH1A1 (0.58) | ALDH1A1LMNAGAAMEN1KMT2A | |
| SCHEMBL16985301 | 0.73 | HTT (0.52) | HTTPOLBALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | HTT 3243/4885POLB 2747/4885ALDH1A1 1077/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | HTT 3609/4885POLB 2709/4885ALDH1A1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.